Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GILD

How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7.

Benzinga

Are Wall Street Analysts Bullish on Gilead Sciences Stock?

Gilead Sciences has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.

Barchart

The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

Barchart

Is Gilead Sciences Stock Outperforming the S&P 500?

While Gilead Sciences has outperformed the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

Barchart

What Are Wall Street Analysts' Target Price for Gilead Sciences Stock?

Gilead Sciences has considerably outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

MarketBeat

Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.

Barchart

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

Barchart

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

Dividend stocks aren't just for long-term income generation. These three shares have jumped 15% in one month while also offering dividend payouts.

MarketBeat

How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?

As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthcare Stocks Tackling America’s Biggest Medical Challenges

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

StockNews.com

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

MarketBeat

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Barchart

Stock Index Futures Slip on Trump Tariffs, Powell’s Testimony on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President Donald Trump and looked ahead to Federal Reserve Chair Jerome Powell’s congressional testimony as well as Wednesday’s release…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

Barchart

Gilead Sciences Stock: Is Wall Street Bullish or Bearish?

Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook.

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth. Thus, investing in fundamentally stable stocks, Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD), could be a wise way to capitalize on the industry’s growing momentum. Read more….

Barchart

Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences is likely to report its fiscal fourth-quarter earnings next month, and analysts are expecting a modest fall in its earnings.

StockNews.com

3 Biotech Stocks Innovating the Future of Medicine

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more.

StockNews.com

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

StockNews.com

3 Biotech Stocks With Promising Pipelines

The biotech sector’s AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.